Advancing cancer therapies. At the speed of light

Advancing cancer therapies. At the speed of light.

Hemerion® develops a unique and disruptive technology to treat glioblastoma.

A disruptive technology to tackle brain cancer and glioblastoma

News

Surgery performed at Lille University Hospital on a patient with glioblastoma. The resection procedure is followed by the use of technology developed by Hemerion to target cancer cells.

Clinical Database Lock Completed for the HTX-GBM-01 Trial

November 19, 2026

Hemerion completed the database lock for its HTX-GBM-01 clinical study on September 28, 2026. This key clinical development milestone formally closes data collection and marks the start of the final… ...

Read more

Hemerion is granted new patents in the US and Japan.

Hemerion is accelerating its international expansion with the granting of new patents in the United States and Japan

September 9, 2026

In late July 2026, Hemerion was notified of the granting of new patents in two major healthcare markets: the United States and Japan. This international expansion strengthens Hemerion’s intellectual property… ...

Read more

Hemerion research grant

Hemerion Research Grant: Two International Awards Presented and a New Edition Announced

July 9, 2026

To broaden the scope of its research, Hemerion funds initiatives and projects led by scientists or clinical teams capable of offering new perspectives on concrete challenges in the fight against… ...

Read more

mail icon

Stay tuned to our clinical advances

Subscribe to our newsletter

They talk about us

Logo Le Point
Logo Biotech Finances
La voix du Nord
Logo Le Moci
Logo BFM TV Grand Lille
Top Santé Logo
Logo France Info
Logo Pharmaceutiques
Logo Euradio
Hemerion sur BFM TV
Logo Maddyness
Logo Mind Health